Kiniksa Pharmaceuticals share price logo

Kiniksa Pharmaceuticals

NASDAQ: KNSA

Mid Cap

$92.86

+2.06

(+2.27%)

Live

as on

Kiniksa Pharmaceuticals Stock Performance

as on November 4, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $91.00
    $94.84
    downward going graph

    2.00%

    Downside

    2.13%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $36.56
    $98.48
    downward going graph

    60.63%

    Downside

    6.05%

    Upside

    downward going graph

Kiniksa Pharmaceuticals share price movements today

Previous Close
$90.80
Open
$91.00
Volume
716.1K
Market Cap
$7.2B
Day's Low - High
$91.00 - $94.84
52 Week Low - High
$36.56 - $98.48

Kiniksa Pharmaceuticals Historical Returns

1 Month Return
+ 19.8 %
3 Month Return
+ 23.69 %
1 Year Return
+ 142.33 %
3 Year Return
+ 460.49 %
5 Year Return
+ 502.92 %

Kiniksa Pharmaceuticals Stock Fundamentals & Key Indicators

Check Kiniksa Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.2B

EPS (TTM)

1.43

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

1.44%

PE Ratio (TTM)

64.5

Industry PE ratio

20.98

PEG Ratio

0.34

EBITDA

144.1M

Revenue (TTM)

946.0M

Profit Margin

54.26%

Return On Equity TTM

17.27%

Kiniksa Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kiniksa Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$7.2B502.92%64.5054.26%0.00%
Buy$43.9BNA67.0247.54%1.02%
StrongBuy$25.7B193.36%19.8186.14%0.00%
Buy$21.5B40.60%-52.0034.83%2.56%
Buy$37.6BNA17.6165.57%1.43%

Stock Returns calculator for Kiniksa Pharmaceuticals Stock including INR - Dollar returns

The Kiniksa Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Kiniksa Pharmaceuticals investment value today

Current value as on today

₹2,64,630

Returns

₹1,64,630

(+164.63%)

Returns from Kiniksa Pharmaceuticals Stock

₹1,47,825 (+147.82%)

Dollar Impact

₹16,805 (+16.81%)

Analyst Recommendation on Kiniksa Pharmaceuticals Stock

Based on 5 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 5 analysts, 100% of analysts recommend a 'BUY' rating for Kiniksa Pharmaceuticals. Average target price of $106.14

Kiniksa Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Kiniksa Pharmaceuticals.

What analysts predicted

12.51%UPSIDE

Target Price

$106.14

Current Price

$92.86

Analyzed by

5 Analysts

High

$122

Target

$106.14

Low

$98

Kiniksa Pharmaceuticals target price $106.14, a slight upside of 12.51% compared to current price of $92.86. According to 5 analysts rating.

Indian Investors' Interest in Kiniksa Pharmaceuticals Stock

Search interest for Kiniksa Pharmaceuticals Stock has increased by 105% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:105% versus previous 30 day period

Kiniksa Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
108
112
122
137
156
180
202
214
243
285
Gross Profit
66
62
56
76
85
97
111
117
131
152
Operating Income
0
-9
-19
13
20
24
19
29
27
54
EBITDA
2
-6
-16
15
23
27
23
33
27
59
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
2
-7
-16
15
22
27
23
32
31
59
Income Tax Expense
6
5
-8
7
5
8
9
10
5
11
Net Income
-3
-12
-8
8
17
18
14
22
25
47
Net Profit Margin
60.92%
55.96%
46.00%
55.25%
54.70%
53.78%
54.93%
55.02%
54.17%
53.29%

Kiniksa Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
38
220
270
423
677
Gross Profit
0
0
-3
-3
29
197
213
362
370
Operating Income
-65
-108
-169
-157
-156
9
-25
-45
77
EBITDA
-65
-107
-161
-153
-154
13
-14
-34
90
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
0
0
2
2
2
2
2
1
1
Income Before Tax
-64
-103
-163
-156
-156
11
-16
-36
88
Income Tax Expense
0
0
-2
5
1
-172
-30
7
29
Net Income
-64
-103
-161
-161
-157
183
14
-43
59
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
76.39%
89.60%
79.09%
85.61%
54.63%

Kiniksa Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-3
-12
-8
8
17
18
-87
22
25
47
Operating Cash Flow
5
-2
18
22
28
33
53
50
47
47
Investing Cash Flow
-46
-6
65
-51
-3
-62
-70
-31
-73
-138
Financing Cash Flow
0
6
2
2
10
11
7
6
6
3
Change in Cash
-41
-1
86
-26
34
-17
-9
24
-20
-88

Kiniksa Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-64
-103
-161
-161
-157
183
14
-43
-43
Operating Cash Flow
-50
-81
-158
-136
-126
5
13
25
25
Investing Cash Flow
0
-239
49
-23
128
-8
-29
37
37
Financing Cash Flow
39
346
84
227
5
2
1
12
12
Change in Cash
-10
26
-25
67
8
0
-14
75
75

Global Institutional Holdings in Kiniksa Pharmaceuticals

Check out the Institutions with significant holdings in Kiniksa Pharmaceuticals.

Funds
Holdings
Vanguard
7.00%
Felix Baker
5.80%
VANGUARD INDEX FUNDS
5.78%
Baker Bros. Advisors Lp
5.68%
BlackRock, Inc.
5.61%

Kiniksa Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 27 October

    Tue, 09:13 PM

    -

    Kiniksa Pharmaceuticals hits 52-week high after Q3 results beat expectations and full-year outlook raised for ARCALYST.

Insights on Kiniksa Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, KNSA stock has moved up by 19.8%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, KNSA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, 14.19M → 47.34M (in $), with an average increase of 31.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, KNSA has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 11 quarters, 79.85M → 285.97M (in $), with an average increase of 11.8% per quarter

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
OrganisationKiniksa Pharmaceuticals
Headquarters105 Piccadilly, London, GL, W1J 7NJ, GB
IndustryMedical - Pharmaceuticals
CEOSanj K. Patel

Key Management of Kiniksa Pharmaceuticals

Name

Title

Mr. Douglas J. Barry

Senior VP, Chief Legal Officer & Secretary

Mr. Joseph Pirrello

Chief Business Officer

Dr. John F. Paolini FACC, M.D., Ph.D.

Executive VP & Chief Medical Officer

Mr. Eben Tessari

Consultant

Mr. Jonathan Kirshenbaum

Investor Relations Officer

Ms. Martina Struck Ph.D.

Senior VP & Chief Regulatory Officer

Mr. Aaron Young

Chief Intellectual Property Officer

Mr. Sanjiv K. Patel

CEO & Chairman of the Board

Mr. Michael R. Megna CPA

Senior VP & Chief Accounting Officer

Ms. Mei Jang

Senior VP & Chief Technical Officer

FAQs

What is Kiniksa Pharmaceuticals share price today?

Kiniksa Pharmaceuticals share price today is $92.86 as on . Kiniksa Pharmaceuticals share today touched a day high of $94.84 and a low of $91.00.

What is the 52 week high and 52 week low for Kiniksa Pharmaceuticals share?

Kiniksa Pharmaceuticals share touched a 52 week high of $98.48 on and a 52 week low of $36.56 on . Kiniksa Pharmaceuticals stock price today i.e. is trending at $92.86,which is 5.71% down from its 52 week high and 153.99% up from its 52 week low.

What is Kiniksa Pharmaceuticals's market capitalisation today?

Kiniksa Pharmaceuticals market capitalisation is $0.01T as on .

How to invest in Kiniksa Pharmaceuticals Stock (KNSA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kiniksa Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Kiniksa Pharmaceuticals Stock (KNSA) from India?

Indian investors can start investing in Kiniksa Pharmaceuticals (KNSA) shares with as little as ₹94.73999786376953 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹947.40 in Kiniksa Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Kiniksa Pharmaceuticals share’s latest price of $92.86 as on November 4, 2026 at 1:29 am IST, you will get 0.1077 shares of Kiniksa Pharmaceuticals. Learn more about fractional shares .

What are the returns that Kiniksa Pharmaceuticals has given to Indian investors in the last 5 years?

Kiniksa Pharmaceuticals stock has given 502.92% share price returns and 27.47% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?